正在加载公司
Just reported
Q3 2026 results
From Biogen's results release of 2026年10月28日; its quarterly report has since been filed.
Revenue
Actual
US$2.8B
+11% y/y
+2.5% q/qGuided
—
No guide given
EPS, GAAP
Actual
-US$0.14
Guided
—
No guide given
Company outlook
Full year 2026
- EPS, adjustedUS$12.20 – US$13.00First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$1.36TA+
JNJJohnson & JohnsonUS$688.6BA+
MRKMerck & Co., Inc.US$364.3BA
NVSNovartis AGUS$306.3BA
AMGNAmgen Inc.US$251.9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
怎么赚钱
- Sales of prescription medicines72%
- Anti-CD20 medicine royalties and profit shares18%
- Contract manufacturing, royalties and related revenue8%
- Alzheimer’s medicine collaboration2%
各项收入占比是对nine months ended September 30, 2026的估算，并非来自已提交报告的数字。
竞争对手
- LLYEli Lilly and CompanyA
- 规模
- US$1.36T
- 利润率
- 31.9%
- RHHBYRoche Holding AG
- NVSNovartis AGA
- 规模
- US$306.3B
- 利润率
- -0.1%
卖什么6
SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.
再显示 3 项
SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.
谁在买4
- Wholesale distributors buy medicines in bulk for resale; a pair of distributors together accounted for 43.9% of gross product revenue (FY 2025, high).
- Specialty pharmacies and specialty distributors handle medicines that require specific storage, delivery or patient support.
- Hospitals, clinics and physicians prescribe or administer Biogen medicines and help patients obtain them.
- Government health programs and private insurers cover or reimburse the cost of many treatments.
靠什么支撑，什么会击垮它
业务依赖什么
- 1Biogen relies on collaborators for some medicines’ development, manufacturing or sales, including Eisai, Ionis, Genentech, Supernus and Samsung Bioepis.
- 2A pair of wholesale distributors accounted for 43.9% of gross product revenue (FY 2025, high).
- 3Sales depend on regulatory approval, continued patent or other market protection, and coverage and reimbursement from government programs and private insurers.
可能出什么问题
- 1Generic and biosimilar medicines, as well as newer competing treatments, can reduce sales or prices; generic versions of TECFIDERA and a biosimilar version of TYSABRI already compete with those products.
- 2Clinical studies can fail, take longer than planned or lead regulators to reject a medicine, limiting revenue from new products and additional uses of existing medicines.
- 3Changes to drug-price rules, insurance coverage or reimbursement can restrict patient access or lower the amount Biogen receives for its medicines.
关于Biogen Inc.
Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.
- 总部
- Cambridge, Massachusetts
- 成立于
- 1978
- 上市于
- NASDAQ
- 财年结束
- December 31
基于 Biogen Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。